Traws Pharma reported a net loss of $3.0 million, or $0.16 per share, for the quarter ended June 30, 2026, compared to a $0.9 million loss in the prior year period. The company held $5.0 million in cash and cash equivalents as of June 30, 2026. Traws is advancing its lead candidate, tivoxavir marboxil, toward an MHRA resubmission for a Phase 2a human influenza Challenge study by the end of Q3 2026, while working to resolve an FDA clinical hold in the U.S. The company completed a private placement in April 2026 that delivered $10.0 million in upfront proceeds and secured shareholder approval for Series B and C warrant tranches, enabling access to up to $50.0 million in additional milestone-based financing. Traws Pharma is a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases.
